Clinical Trial Detail

NCT ID NCT04095273
Title Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bayer
Indications

renal carcinoma

lung non-small cell carcinoma

transitional cell carcinoma

Her2-receptor negative breast cancer

ovarian cancer

prostate cancer

Advanced Solid Tumor

hepatocellular carcinoma

fallopian tube cancer

peritoneum cancer

stomach cancer

Therapies

BAY1895344 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.